GlassScriptPhysician profile
Melanie A Lerner
NPI 1912324468
$2,724.74
in general payments reported to CMS, 2019-2025
20 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $24.32 · 2024: $1,319 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,724.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $412.20 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $412.17 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $406.05 | 2024-2025 | Evenity, Prolia |
| Corcept Therapeutics | $191.45 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $184.70 | 2024-2025 | Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.26 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $149.09 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $129.67 | 2024-2025 | Isturisa, Signifor Lar |
| Ascendis Pharma Endocrinology INC | $115.16 | 2025 | Yorvipath |
| Antares Pharma, INC. | $97.99 | 2024-2025 | Xyosted |
| Sanofi-Aventis U.S. LLC | $88.20 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $81.40 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $62.33 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $46.44 | 2024 | Nexletol |
| Amneal Pharmaceuticals LLC | $44.11 | 2025 | Unithroid |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $41.62 | 2025 | Tymlos |
| Insulet Corporation | $28.37 | 2025 | Omnipod |
| Dexcom, INC. | $27.27 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $24.32 | 2023 | Arexvy, Shingrix |
| Beta Bionics, INC. | $21.94 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.